

CITATION REPORT

List of articles citing

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

DOI: 10.1111/bju.13549

BJU International, 2017, 119, 522-529.

Source: <https://exaly.com/paper-pdf/65880444/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Zoledronic acid and Sr89 cost effective in prostate cancer. <i>PharmacoEconomics & Outcomes News</i> , 2016 , 756, 36-36	0.1	
17	The role of bone-targeted therapies for prostate cancer in 2017. <i>Current Opinion in Supportive and Palliative Care</i> , 2017 , 11, 216-224	2.6	3
16	Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. <i>Pharmacoeconomics</i> , 2017 , 35, 1223-1236	4.4	32
15	Bisphosphonates for advanced prostate cancer. <i>The Cochrane Library</i> , 2017 , 12, CD006250	5.2	20
14	New horizons in the management of castrate-resistant prostate cancer. <i>Journal of Clinical Urology</i> , 2018 , 11, 258-265	0.2	2
13	Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2018 , 36, 301-322	4.4	9
12	Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. <i>PLoS ONE</i> , 2018 , 13, e0208063	3.7	14
11	Combining anticancer drugs with osteoprotective agents in prostate cancer-A contemporary update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 488-497	2.8	
10	Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials. <i>BMC Cancer</i> , 2019 , 19, 332	4.8	3
9	Measuring Quality-Adjusted Life-Years When Health Fluctuates. <i>Value in Health</i> , 2020 , 23, 343-350	3.3	9
8	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. <i>The Cochrane Library</i> , 2020 , 12, CD013020	5.2	8
7	A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 1685-1728	4	1
6	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. <i>Health Technology Assessment</i> , 2016 , 20, 1-288	4.4	20
5	Targeted Radionuclide Therapy for Bone Metastasis. 2016 , 1-29		
4	Targeted Radionuclide Therapy for Bone Metastasis. 2017 , 1307-1335		
3	Targeted Radionuclide Therapy for Bone Metastasis. 2022 , 1-33		
2	Estimating Quality of Life Decrements in Oncology Using Time to Death. <i>Value in Health</i> , 2022 ,	3.3	0

1 Targeted Radionuclide Therapy for Bone Metastasis. **2022**, 1481-1513 o